Deutsche Bank Starts BrightSpring Health (BTSG) at Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
UBS Starts BrightSpring Health (BTSG) at Buy
February 20, 2024 6:53 AM ESTUBS analyst AJ Rice initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Buy rating and a price target of $15.00.
The analyst comments "We initiate coverage of BrightSpring with a Buy rating and a $15 price target. Bottom line, BrightSpring offers attractive... More
Wells Fargo Starts BrightSpring Health (BTSG) at Overweight
February 20, 2024 5:15 AM ESTWells Fargo initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Overweight rating and a price target of $15.00.
For an analyst ratings summary and ratings history on BrightSpring Health click here. For more ratings news on BrightSpring Health click here.
Shares of BrightSpring Health closed at $10.71 yesterday.
... MoreMorgan Stanley Starts BrightSpring Health (BTSG) at Overweight, 'A Bright Vision'
February 20, 2024 3:28 AM ESTMorgan Stanley analyst Erin Wright initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Overweight rating and a price target of $18.00.
The analyst commented: "BrightSpring's diversified healthcare services offering across both pharmacy and provider solutions offers multiple avenues for growth... More
Goldman Sachs Starts BrightSpring Health (BTSG) at Buy, 'Compelling Platform with Durable Drivers and Multiple Upside Opportunities
February 20, 2024 2:46 AM EST(Updated - February 20, 2024 3:47 AM EST)
Goldman Sachs analyst Jamie Perse initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Buy rating and a price target of $26.00.
The analyst said: "BTSG is a scaled national healthcare services company focused on providing pharmacy services and patient-level care to patients in the home and community settings.... More
Jefferies Starts BrightSpring Health (BTSG) at Buy, 'De-Leveraging Story, Compelling Valuation'
February 20, 2024 2:26 AM EST(Updated - February 20, 2024 3:54 AM EST)
Jefferies analyst Brian Tanquilut initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Buy rating and a price target of $18.00.
The analyst commented: "
BTSG Should See High-Single-Digit Organic EBITDA Growth, Driven Primarily by Tailwinds in Specialty Rx. We view BTSG as a healthy (+7% to +9%) organic growth story, and we see the bulk of this growth in its Specialty & Infusion segment (~50% of revs). The robust pipeline of new biotech drugs under development... More
